Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03886831
Previous Study | Return to List | Next Study

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03886831
Recruitment Status : Recruiting
First Posted : March 22, 2019
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
Prelude Therapeutics

Brief Summary:
This is a Phase 1 cohort, dose-escalation study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory Advanced Solid Tumors Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma Relapsed/Refractory Myelodysplasia Relapsed/Refractory Myelofibrosis Drug: PRT543 Phase 1

Detailed Description:
This is a multicenter, open-label, sequential-cohort, dose-escalation Phase 1 study of PRT543 in patients with advanced cancers who have exhausted available treatment options. Enrollment will take place concurrently into two distinct patient groups (one for solid tumors/lymphomas and one for hematological malignancies). The study will consist of 2 parts, a dose escalation part, and once the recommended phase 2 dose (RP2D) has been determined, a cohort expansion part with four separate cohorts. For patients, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. An end-of-study visit will be conducted within 30 days after the last dose of PRT543.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Actual Study Start Date : February 11, 2019
Estimated Primary Completion Date : August 11, 2021
Estimated Study Completion Date : August 11, 2022


Arm Intervention/treatment
Experimental: PRT543
PRT543 will be administered orally
Drug: PRT543
PRT543 will be administered orally




Primary Outcome Measures :
  1. To describe dose limiting toxicities (DLT) of PRT543 [ Time Frame: Baseline through Day 28. ]
    Dose limiting toxicities (DLTs) will be evaluated during the first cycle

  2. To determine the maximally tolerated dose (MTD) [ Time Frame: Baseline through approximately 2 years. ]
    The maximum tolerated dose (MTD) will be established for further investigation in participants with advanced malignancies who have failed prior treatments.

  3. To determine the recommended phase 2 dose (RP2D) and schedule of PRT543 [ Time Frame: Baseline through approximately 2 years. ]
    The recommended phase 2 dose (RP2D) and optimal dosing schedule of PRT543 will be established for further investigation in participants with advanced malignancies who have failed prior treatments.


Secondary Outcome Measures :
  1. To describe the adverse event profile and tolerability of PRT543 [ Time Frame: Baseline through approximately 2 years ]
    Adverse events as characterized by type, frequency, severity, timing, seriousness and relationship to study therapy

  2. To determine the maximum observed plasma concentration (Cmax) of PRT543 [ Time Frame: Cycle 1 (each cycle is 28 days) on Days 1 and 25: predose and 0.5, 1, 2, 4, 8, 24 hours postdose; predose on Cycle 1, Days 4, 8, 11, 22. Subsequently for Cycle 2 and beyond (until end of study treatment) on Day 1. ]
    PRT543 pharmacokinetics will be calculated including the maximum observed plasma concentration.

  3. To determine the time to reach maximum observed plasma concentration (Tmax) of PRT543 [ Time Frame: Cycle 1 (each cycle is 28 days) on Days 1 and 25: predose and 0.5, 1, 2, 4, 8, 24 hours postdose; predose on Cycle 1, Days 4, 8, 11, 22. Subsequently for Cycle 2 and beyond (until end of study treatment) on Day 1. ]
    PRT543 pharmacokinetics will be calculated including the time to reach maximum observed plasma concentration


Other Outcome Measures:
  1. To determine the terminal elimination half-life (t1/2) of PRT543. [ Time Frame: Cycle 1 (each cycle is 28 days) on Days 1 and 25: predose and 0.5, 1, 2, 4, 8, 24 hours postdose; predose on Cycle 1, Days 4, 8, 11, 22. Subsequently for Cycle 2 and beyond (until end of study treatment) on Day 1. ]
    PRT543 pharmacokinetics will be calculated including the terminal elimination half life

  2. To determine the area under the plasma concentration versus time curve (AUC) of PRT543 [ Time Frame: Cycle 1 (each cycle is 28 days) on Days 1 and 25: predose and 0.5, 1, 2, 4, 8, 24 hours postdose; predose on Cycle 1, Days 4, 8, 11, 22. Subsequently for Cycle 2 and beyond (until end of study treatment) on Day 1. ]
    PRT543 pharmacokinetics will be calculated including area under the plasma concentration versus time curve.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic or advanced solid tumor; or advanced diffuse large B-cell lymphoma; or advanced mantle cell lymphoma; or relapsed myelodysplastic syndrome; or relapsed myelofibrosis. All malignancies must be refractory to established therapies
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1
  • Adequate organ function (bone marrow, hepatic, renal, cardiovascular)
  • Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial

Exclusion Criteria:

  • Primary malignancies of the Central Nervous System(CNS) or uncontrolled CNS metastases
  • Requirement of pharmacologic doses of glucocorticoids
  • Prior treatment with chimeric antigen receptor T cells (CAR-T cells)
  • HIV positive; known active hepatitis B or C
  • Known hypersensitivity to any of the components of PRT543
  • Prior allogeneic bone marrow transplant; autologous hematopoietic transplantation less than 100 days since transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03886831


Locations
Layout table for location information
United States, Florida
Florida Cancer Specialist Recruiting
Sarasota, Florida, United States, 34232
Contact: Study Contact    615-329-7274    CANN.REFMAL605@SarahCannon.com   
United States, Ohio
The Ohio State University and Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Study Contact    615-329-7274    CANN.REFMAL605@SarahCannon.com   
United States, Tennessee
PLLC Recruiting
Nashville, Tennessee, United States, 37203
Contact: Study Contact    615-329-7274    CANN.REFMAL605@SarahCannon.com   
Sponsors and Collaborators
Prelude Therapeutics

Layout table for additonal information
Responsible Party: Prelude Therapeutics
ClinicalTrials.gov Identifier: NCT03886831     History of Changes
Other Study ID Numbers: PRT543-01
First Posted: March 22, 2019    Key Record Dates
Last Update Posted: June 12, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, Large B-Cell, Diffuse
Primary Myelofibrosis
Myelodysplastic Syndromes
Preleukemia
Lymphoma, Non-Hodgkin
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions